AMELIORATIVE EFFECTS OF SELECTIVE PDE-10 INHIBITORS AGAINST KETAMINE-MEDIATED SCHIZOPHRENIC OUTCOMES IN MICE
DOI:
https://doi.org/10.22159/ajpcr.2026v19i1.55825Keywords:
Schizophrenia, Phosphodiesterase, Inflammation, Cognition, Social withdrawal, Open fieldAbstract
Objectives: Schizophrenia (SCZ) is characterized by significant impairments in perception and cognitive flexibility. Making accurate plans for therapy demands a deeper comprehension of the brain mechanisms behind these disorders. The purpose of our investigation is to analyze the protective effects of papaverine, a phosphodiesterase-10 inhibitor, on ketamine-induced SCZ -like behavioral and biochemical alterations in mice.
Methods: For 10 consecutive days, mice were exposed to ketamine (30 mg/kg; i.p.) to develop a SCZ-like phenotype. Various behavioral tests, including social interactions, catalepsy, cognitive impairment (Morris water maze), locomotor and anxiety (open field test), and immobility duration (forced swim test), were assessed. Biochemicals (acetylcholinesterase [AChE] activity, glutathione, and lipid peroxides), and histopathological alterations were also investigated. In this study, papaverine (30 mg/kg; i.p.) and clozapine (7.5 mg/kg p.o.) served as test and standard, respectively. Results were statistically analyzed and “one-way ANOVA” was performed, and Tukey’s multiple comparison test was subsequently applied.”
Results: After 28 days of ketamine therapy, significant (p≤0.05) behavioral alterations have been noted, including increased immobility duration, altered locomotor and anxiety-like behaviors, social interactions, cognitive impairment, and catalepsy. Significant alterations in histopathology, AChE activity, and oxidative stress (increased lipid peroxides and lower glutathione) were also observed in mice treated with ketamine. Treatment with clozapine and papaverine considerably (p≤0.05) improved the biochemical changes, behavioral problems, and histological changes.
Conclusion: We may conclude that papaverine may have neurodefensive effects against ketamine-induced SCZ in mice based on behavioral, histological, and biochemical observations.
Downloads
References
1. Volkan K. Schizophrenia: Epidemiology, causes, neurobiology, pathophysiology, and treatment. J Health Med Sci. 2020 Nov;3(4): 487-521.
2. McCutcheon RA, Reis Marques TR, Howes OD. Schizophrenia-an overview. JAMA Psychiatry. 2020 Feb 1;77(2):201-10. doi: 10.1001/ jamapsychiatry.2019.3360, PMID 31664453
3. Menon V. Brain networks and cognitive impairment in psychiatric disorders. World Psychiatry. 2020 Sep 15;19(3):309-10. doi: 10.1002/ wps.20799, PMID 32931097
4. Shrivastava A, Aggarwal R, Singh RP, Khabiya R. A mini review on properties, mechanism of action, pharmacokinetic and pharmacodynamics and analytical methods of cariprazine. Int J App Pharm. 2023;15(1):31-5. doi: 10.22159/ijap.2023v15i1.46651
5. Moura BM, Isvoranu AM, Kovacs V, Van Rooijen G, Van Amelsvoort T, Simons CJ, et al. The puzzle of functional recovery in schizophrenia-spectrum disorders-replicating a network analysis study. Schizophr Bull. 2022 Jul 1;48(4):871-80. doi: 10.1093/schbul/sbac018, PMID 35266000
6. Pannu AS, Parle M. Anti-psychotic activity of Pyrus communis juice. Int J Pharm Pharm Sci. 2017;9(4):113-20. doi: 10.22159/ ijpps.2017v9i4.14541
7. Yao JK, Dougherty GG, Reddy RD, Keshavan MS, Montrose DM, Matson WR, et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry. 2010 Sep;15(9):938-53. doi: 10.1038/mp.2009.33, PMID 19401681
8. Olney JW, Labruyere J, Wang G, Wozniak DF, Price MT, Sesma MA. NMDA antagonist neurotoxicity: Mechanism and prevention. Science. 1991 Dec 6;254(5037):1515-8. doi: 10.1126/science.1835799, PMID 1835799
9. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994 Mar 1;51(3): 199-214. doi: 10.1001/archpsyc.1994.03950030035004, PMID 8122957
10. Mendes PF, Simon KA, Hueza IM. Toxic and immunotoxic evaluation of ketamine and/or ethanol in rats during 28 days. Int J Pharm Pharm Sci. 2017;9(9):205-14. doi: 10.22159/ijpps.2017v9i9.20582
11. Samidurai A, Xi L, Das A, Iness AN, Vigneshwar NG, Li PL, et al. Role of phosphodiesterase 1 in the pathophysiology of diseases and potential therapeutic opportunities. Pharmacol Ther. 2021 Oct 1;226:107858. doi: 10.1016/j.pharmthera.2021.107858, PMID 33895190
12. Ahmad F, Murata T, Shimizu K, Degerman E, Maurice D, Manganiello V. Cyclic nucleotide phosphodiesterases: Important signaling modulators and therapeutic targets. Oral Dis. 2015 Jan;21(1):e25-50. doi: 10.1111/ odi.12275, PMID 25056711
13. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, et al. Inhibition of the striatum-enriched phosphodiesterase PDE10A: A novel approach to the treatment of psychosis. Neuropharmacology. 2006 Aug 1;51(2):386-96. doi: 10.1016/j. neuropharm.2006.04.013, PMID 16780899
14. Threlfell S, Sammut S, Menniti FS, Schmidt CJ, West AR. Inhibition of phosphodiesterase 10A increases the responsiveness of striatal projection neurons to cortical stimulation. J Pharmacol Exp Ther. 2009 Mar 1;328(3):785-95. doi: 10.1124/jpet.108.146332, PMID 19056933
15. Kantrowitz JT, Javitt DC. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: The final common pathway on the road to schizophrenia? Brain Res Bull. 2010 Sep 30;83(3-4):108-21. doi: 10.1016/j.brainresbull.2010.04.006, PMID 20417696
16. Howes OD, Kapur S. The dopamine hypothesis of schizophrenia: Version III--the final common pathway. Schizophr Bull. 2009 May 1; 35(3):549-62.
17. Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, et al. Preclinical characterization of selective phosphodiesterase 10A inhibitors: A new therapeutic approach to the treatment of schizophrenia. J Pharmacol Exp Ther. 2008 May 1;325(2):681-90. doi: 10.1124/jpet.107.132910, PMID 18287214
18. Grauer SM, Pulito VL, Navarra RL, Kelly MP, Kelley C, Graf R, et al. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia. J Pharmacol Exp Ther. 2009 Nov 1;331(2):574-90. doi: 10.1124/ jpet.109.155994, PMID 19661377
19. Chatterjee M, Jaiswal M, Palit G. Comparative evaluation of forced swim test and tail suspension test as models of negative symptom of schizophrenia in rodents. Int Sch Res Not. 2012;2012(1):595141. doi: 10.5402/2012/595141, PMID 23738205
20. Patel DS, Anand IS, Bhatt PA. Evaluation of antidepressant and anxiolytic activity of phosphodiesterase 3 inhibitor-cilostazol. Indian J Psychol Med. 2012 Apr;34(2):124-8. doi: 10.4103/0253-7176.101776, PMID 23162186
21. Shougrakpam P, Bhattacharjee A, Medhabati M, Gunindro N. Comparative study of antidepressant-like effect of the leaves of Sapindus emarginatus and Acorus calamus in experimental animal models. Int J Curr Pharm Res. 2021 Jan 15;13:28-31.
22. Kraeuter AK, Guest PC, Sarnyai Z. The open field test for measuring locomotor activity and anxiety-like behavior. Methods Mol Biol. 2019 Dec 11;1916:99-103.
23. Seibenhener ML, Wooten MC. Use of the open field maze to measure locomotor and anxiety-like behavior in mice. J Vis Exp. 2015 Feb;6(96):e52434. doi: 10.3791/52434, PMID 25742564
24. Batool F, Kamal A, Sattar M, Shah HA, Ahmed DS. Evaluation of antidepressant activity of aqueous extract of sea buckhorn fruit in experimental model of depression. Pak J Bot. 2011;43(3):1595-9.
25. Dubey NE, Agrawal OP, Gidwani BI. Optimization, characterization and in vivo study of rivastigmine tartrate nanoparticles by using 22 full factorial design for oral delivery. Int J App Pharm. 2023;15(3):80-9. doi: 10.22159/ijap.2023v15i3.47140
26. Singh P, Sharma B. Agonism of histaminergic-H1 receptors in ischemic postconditioning during cerebral ischemia-reperfusion injury is protective. Curr Neurovasc Res. 2020 Dec 1;17(5):686-99. doi: 10.217 4/1567202617666201214105720, PMID 33319685
27. Vorhees CV, Williams MT. Morris water maze: Procedures for assessing spatial and related forms of learning and memory. Nat Protoc. 2006 Aug;1(2):848-58. doi: 10.1038/nprot.2006.116, PMID 17406317
28. Luciani KR, Frie JA, Khokhar JY. An open source automated Bar Test for measuring catalepsy in rats. eNeuro. 2020 May 1;7(3):1-5. doi: 10.1523/ENEURO.0488-19.2020, PMID 32198157
29. Kaidanovich-Beilin O, Lipina T, Vukobradovic I, Roder J, Woodgett JR. Assessment of social interaction behaviors. J Vis Exp. 2011 Feb 25;(48):2473. doi: 10.3791/2473, PMID 21403628
30. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979 Jun 1;95(2):351-8. doi: 10.1016/0003-2697(79)90738-3, PMID 36810
31. Beutler RG. Reduced glutathion estimation. J Lab Clin Med. 1963;61:82.
32. Ellman GL, Courtney KD, Andres V Jr., Feather-stone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul 1;7(2):88-95. doi: 10.1016/0006-2952(61)90145-9, PMID 13726518
33. Gupta VK, Kumar A, Siddiqi NJ, Sharma B. Rat brain acetylcholinesterase as a biomarker of cadmium induced neurotoxicity. J Toxicol. 2016 Jan 8;1(1):001-7.
34. You W, Zuo G, Shen H, Tian X, Li H, Zhu H, et al. Potential dual role of nuclear factor-kappa B in experimental subarachnoid hemorrhage-induced early brain injury in rabbits. Inflamm Res. 2016;65(12): 975-84. doi: 10.1007/s00011-016-0980-8, PMID 27554683
35. Khalid I, Saleem U, Ahmad B, Hawwal MF, Mothana RA. NMDA receptor modulation by Esculetin: Investigating behavioral, biochemical and neurochemical effects in schizophrenic mice model. Saudi Pharm J. 2024 Apr 1;32(4):101994. doi: 10.1016/j.jsps.2024.101994, PMID 38405040
36. Adell A. Brain NMDA receptors in schizophrenia and depression. Biomolecules. 2020 Jun 23;10(6):947. doi: 10.3390/biom10060947, PMID 32585886
37. Hope S, Hoseth E, Dieset I, Mørch RH, Aas M, Aukrust P, et al. Inflammatory markers are associated with general cognitive abilities in schizophrenia and bipolar disorder patients and healthy controls. Schizophr Res. 2015 Jul 1;165(2-3):188-94. doi: 10.1016/j. schres.2015.04.004, PMID 25956633
38. Hajizadeh Moghaddam A, Malekzadeh Estalkhi F, Khanjani Jelodar S, Ahmed Hasan T, Farhadi-Pahnedari S, Karimian M. Neuroprotective effects of alpha-pinene against behavioral deficits in ketamine-induced mice model of schizophrenia: Focusing on oxidative stress status. IBRO Neurosci Rep. 2024 Jun 1;16:182-9. doi: 10.1016/j.ibneur.2023.12.012, PMID 38318342
39. Abdel-Salam OM, El-Shamarka M, Omara EA. Brain oxidative stress and neurodegeneration in the ketamine model of schizophrenia during antipsychotic treatment: Effects of N-acetylcysteine treatment. React Oxygen Species. 2018 Jul 1;6(16):253-66. doi: 10.20455/ ros.2018.839
40. Vasconcelos GS, Ximenes NC, De Sousa CN, Oliveira T, Lima LL, De Lucena DF, et al. Alpha-lipoic acid alone and combined with clozapine reverses schizophrenia-like symptoms induced by ketamine in mice: Participation of antioxidant, nitrergic and neurotrophic mechanisms. Schizophr Res. 2015 Jul 1;165(2-3):163-70. doi: 10.1016/j. schres.2015.04.017, PMID 25937462
41. McCutcheon RA, Abi-Dargham A, Howes OD. Schizophrenia, dopamine and the striatum: From biology to symptoms. Trends Neurosci. 2019 Mar 1;42(3):205-20. doi: 10.1016/j.tins.2018.12.004, PMID 30621912
42. Sobota R, Mihara T, Forrest A, Featherstone RE, Siegel SJ. Oxytocin reduces amygdala activity, increases social interactions, and reduces anxiety-like behavior irrespective of NMDAR antagonism. Behav Neurosci. 2015 Aug;129(4):389-98. doi: 10.1037/bne0000074, PMID 26214213
43. Ben-Azu B, Adebayo OG, Fokoua AR, Oritsemuelebi B, Chidebe EO, Nwogueze CB, et al. Antipsychotic effect of diosgenin in ketamine-induced murine model of schizophrenia: Involvement of oxidative stress and cholinergic transmission. IBRO Neurosci Rep. 2024 Jun 1;16: 86-97. doi: 10.1016/j.ibneur.2023.12.008, PMID 38282757
44. De Araújo FY, Chaves Filho AJ, Nunes AM, De Oliveira GV, Gomes PX, Vasconcelos GS, et al. Involvement of anti-inflammatory, antioxidant, and BDNF up-regulating properties in the antipsychotic-like effect of the essential oil of Alpinia zerumbet in mice: A comparative study with olanzapine. Metab Brain Dis. 2021 Dec;36(8):2283-97. doi: 10.1007/ s11011-021-00821-5, PMID 34491479
45. Monte AS, De Souza GC, McIntyre RS, Soczynska JK, Dos Santos JV, Cordeiro RC, et al. Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol. 2013 Nov;27(11):1032-43. doi: 10.1177/0269881113503506, PMID 24045882
46. Schiavone S, Tucci P, Trabace L, Morgese MG. Early celastrol administration prevents ketamine-induced psychotic-like behavioral dysfunctions, oxidative stress and IL-10 reduction in the cerebellum of adult mice. Molecules. 2019 Nov 5;24(21):3993. doi: 10.3390/ molecules24213993, PMID 31694174
47. Watkins CC, Andrews SR. Clinical studies of neuroinflammatory mechanisms in schizophrenia. Schizophr Res. 2016 Sep 1;176(1): 14-22. doi: 10.1016/j.schres.2015.07.018, PMID 26235751
48. Monji A, Kato T, Kanba S. Cytokines and schizophrenia: Microglia hypothesis of schizophrenia. Psychiatry Clin Neurosci. 2009 Jun;63(3):257-65. doi: 10.1111/j.1440-1819.2009.01945.x, PMID 19579286
49. Bogerts B, Häntsch J, Herzer M. A morphometric study of the dopamine-containing cell groups in the mesencephalon of normals, Parkinson patients, and schizophrenics. Biol Psychiatry. 1983 Sep 1;18(9): 951-69. PMID 6640008
50. Wang YC, Ho UC, Ko MC, Liao CC, Lee LJ. Differential neuronal changes in medial prefrontal cortex, basolateral amygdala and nucleus accumbens after postweaning social isolation. Brain Struct Funct. 2012 Apr;217(2):337-51. doi: 10.1007/s00429-011-0355-4, PMID 22002740
51. Kokkinou M, Ashok AH, Howes OD. The effects of ketamine on dopaminergic function: Meta-analysis and review of the implications for neuropsychiatric disorders. Mol Psychiatry. 2018 Jan;23(1):59-69. doi: 10.1038/mp.2017.190, PMID 28972576
52. Debatin KM, Poncet D, Kroemer G. Chemotherapy: Targeting the mitochondrial cell death pathway. Oncogene. 2002;21(57):8786-803. doi: 10.1038/sj.onc.1206039, PMID 12483532
53. Hebb AL, Robertson HA. Role of phosphodiesterases in neurological and psychiatric disease. Curr Opin Pharmacol. 2007 Feb 1;7(1):86-92. doi: 10.1016/j.coph.2006.08.014, PMID 17113826
54. Kim JH, Yi HJ, Ko Y, Kim YS, Kim DW, Kim JM. Effectiveness of papaverine cisternal irrigation for cerebral vasospasm after aneurysmal subarachnoid hemorrhage and measurement of biomarkers. Neurol Sci. 2014 May;35(5):715-22. doi: 10.1007/s10072-013-1589-0, PMID 24297765
55. Sabir M, Gupta R, Sindhu RK, Gupta AK. A review on papaverine: A potential neuroprotective agent for cerebral ischemia-reperfusion injury. Biochem Cell Arch. 2024 Oct 2;24(1):3361. doi: 10.51470/ BCA.2024.24.1-S.3361
56. Lee YY, Park JS, Leem YH, Park JE, Kim DY, Choi YH, et al. The phosphodiesterase 10 inhibitor papaverine exerts anti-inflammatory and neuroprotective effects through the PKA signaling pathway in neuroinflammation and Parkinson’s disease mouse models. J Neuroinflammation. 2019 Dec;16(1):246. doi: 10.1186/s12974-019- 1649-3, PMID 31791357
57. Beker MC, Altintas MO, Dogan E, Bayraktaroglu C, Balaban B, Ozpinar A, et al. Inhibition of phosphodiesterase 10A mitigates neuronal injury by modulating apoptotic pathways in cold-induced traumatic brain injury. Mol Cell Neurosci. 2024 Dec 1;131:103977. doi: 10.1016/j.mcn.2024.103977, PMID 39437931
58. Li J, Chen JY, Deng YL, Zhou Q, Wu Y, Wu D, et al. Structure-based design, synthesis, biological evaluation, and molecular docking of novel PDE10 inhibitors with antioxidant activities. Front Chem. 2018 May 15;6:167. doi: 10.3389/fchem.2018.00167, PMID 29868568
59. Luhach K, Kulkarni GT, Singh VP, Sharma B. Effect of papaverine on developmental hyperserotonemia induced autism spectrum disorder related behavioural phenotypes by altering markers of neuronal function, inflammation, and oxidative stress in rats. Clin Exp Pharmacol Physiol. 2021 Apr;48(4):614-25. doi: 10.1111/1440-1681.13459, PMID 33480092
60. Ashrafi S, Alam S, Sultana A, Raj A, Emon NU, Richi FT, et al. Papaverine: A miraculous alkaloid from opium and its multimedicinal application. Molecules. 2023 Mar 31;28(7):3149. doi: 10.3390/ molecules28073149, PMID 37049912
61. Atshan DA, Zalzala MH. Papaverine attenuates the progression of alpha naphthylisothiocyanate induce cholestasis in rats. Curr Res Pharmacol Drug Discov. 2024 Jan 1;6:100177. doi: 10.1016/j.crphar.2024.100177, PMID 38322817
62. Nishi A, Kuroiwa M, Miller DB, O’Callaghan JP, Bateup HS, Shuto T, et al. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/ PKA signaling in the striatum. J Neurosci. 2008 Oct 15;28(42): 10460-71. doi: 10.1523/JNEUROSCI.2518-08.2008, PMID 18923023
63. Birjandi SZ, Abduljawad N, Nair S, Dehghani M, Suzuki K, Kimura H, et al. Phosphodiesterase 10A inhibition leads to brain region-specific recovery based on stroke type. Transl Stroke Res. 2021 Apr;12(2): 303-15. doi: 10.1007/s12975-020-00819-8, PMID 32378029
Published
How to Cite
Issue
Section
Copyright (c) 2025 Prabhat Singh
This work is licensed under a Creative Commons Attribution 4.0 International License.
The publication is licensed under CC By and is open access. Copyright is with author and allowed to retain publishing rights without restrictions.